Amgen hires outside firm to defend Tavneos after FDA withdrawal proposal

What happened

Amgen has engaged an independent research firm to reassess clinical data for Tavneos, a Horizon-acquired rare-disease drug, following a U.S. FDA proposal to withdraw the drug from the market. This defensive move signals that the agency's concerns are serious enough to warrant an outside review, raising doubts about Tavneos's commercial viability. The Horizon acquisition, already under scrutiny for its $28 billion price tag, now faces added pressure as one of its key assets fights for survival. The DeepValue master report had flagged that Horizon asset underperformance was a thesis breaker, and this development accelerates that risk. Meanwhile, Amgen's broader portfolio continues to face erosion from IRA price cuts and biosimilar competition, compounding the negative sentiment.

Implication

For investors, this news crystallizes a key risk flagged in the DeepValue master report: that Horizon assets could underperform relative to expectations. Tavneos is a relatively small drug, but the withdrawal proposal and defensive review signal deeper regulatory and clinical challenges that may extend to other Horizon products like Tepezza and Uplizna. The immediate implication is that Amgen may need to invest additional resources to defend Tavneos, diverting focus from more promising growth drivers like MariTide. Longer term, if Tavneos is withdrawn or its label is restricted, it would reduce the already tenuous growth contribution from Horizon, making it harder to offset legacy erosion. The stock's current valuation (~23.7x P/E) does not adequately discount this scenario, leaving it vulnerable to further downside if other Horizon assets face similar scrutiny.

Thesis delta

The thesis now shifts from a balanced risk of Horizon underperformance to an active regulatory threat that could crystallize sooner than expected. The previously assumed 25% bear case probability should be revised upward, as Tavneos's challenges may signal broader quality issues with Horizon's pipeline. Investors should monitor for similar FDA actions or unfavorable reviews on Tepezza and Uplizna, which would materially impair Amgen's ability to grow through legacy drug erosion.